RNA polymerase inhibitor enisamium for treatment of moderate COVID-19 patients: a randomized, placebo-controlled, multicenter, double-blind phase 3 clinical trial
O. Holubovska, P. Babich, A. Mironenko, J. Milde, Y. Lebed, H. Stammer, L. Mueller, View ORCID ProfileA.J.W. te Velthuis, V. Margitich, A. Goy
doi: https://doi.org/10.1101/2022.08.21.22279036
